Welcome to our dedicated page for FendX Technologies news (Ticker: FDXTF), a resource for investors and traders seeking the latest updates and insights on FendX Technologies stock.
About FendX Technologies Inc.
FendX Technologies Inc. (OTCQB: FDXTF) is a Canada-based nanotechnology company dedicated to creating innovative solutions to enhance public health and safety by reducing the spread of pathogens. The company specializes in developing advanced surface protection coatings designed to minimize contamination on high-touch surfaces across various industries. Leveraging cutting-edge nanotechnology, FendX aims to provide scalable, effective, and sustainable solutions to address critical challenges in infection prevention and control.
Core Products and Technologies
FendX's flagship product, REPELWRAP™ film, is a revolutionary protective surface coating film that utilizes award-winning nanotechnology to repel pathogens, including bacteria and viruses, by over 98%. This innovative film prevents adhesion and reduces transmission on surfaces prone to contamination, making it ideal for healthcare settings, hospitality venues, transportation hubs, and other high-traffic environments. Additionally, the company is developing a bifunctional spray coating that not only repels pathogens but also kills them, offering a versatile solution for various applications.
Research and Development
Research and development are at the heart of FendX's operations. The company collaborates with industry-leading partners, including McMaster University, to advance its nanotechnology. FendX holds exclusive worldwide licenses for its proprietary technology and intellectual property portfolio, encompassing both film and spray coating formulations. This strategic partnership ensures that FendX remains at the forefront of innovation in the nanotechnology space.
Strategic Partnerships and Market Position
FendX has established key collaborations with global industry leaders such as Dunmore International Corp. to optimize and scale the manufacturing of its products. These partnerships enable the company to conduct pilot manufacturing runs and real-world testing across diverse environments, including healthcare facilities, restaurants, fitness centers, and entertainment venues. By working with strategic testing partners, FendX ensures its products meet rigorous performance standards under real-world conditions.
Intellectual Property and Global Reach
FendX is committed to building a robust intellectual property portfolio to protect its groundbreaking technologies. The company has secured patents in multiple jurisdictions, including the United States, Japan, China, and Europe, for its REPELWRAP™ film and related nanotechnology. This global IP strategy underscores FendX's dedication to maintaining a competitive edge in the market while expanding its international presence.
Applications and Market Potential
The company's products have broad applications across various sectors, including healthcare, hospitality, transportation, and public venues. By addressing the critical need for infection prevention, FendX's technologies offer significant value to industries seeking to enhance safety and hygiene standards. The company's ongoing efforts to commercialize its products through licensing and distribution agreements further position it as a key player in the nanotechnology market.
Commitment to Innovation and Collaboration
FendX continuously explores new opportunities to expand its product pipeline and enhance its market offerings. Recent initiatives include the development of AI-enhanced pathogen detection technology and the acquisition of intellectual property related to open-cell foam-based cleaning solutions. These advancements align with the company's mission to provide innovative, disruptive technologies that make people's lives safer.
Conclusion
FendX Technologies Inc. is a pioneering force in the field of nanotechnology, offering cutting-edge solutions to combat pathogen transmission. With a strong focus on R&D, strategic partnerships, and intellectual property protection, the company is well-positioned to meet the growing demand for advanced surface protection products. By leveraging its expertise and innovative technologies, FendX continues to make significant strides toward creating a safer and healthier world.
FendX Technologies (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D), a nanotechnology company focused on surface protection coatings, has granted 55,000 restricted share units (RSUs) to a consultant. The RSUs will vest in three equal portions: on the grant date, December 20, 2024, and January 18, 2025. The grant follows the company's equity incentive plan from October 19, 2021, and includes a mandatory hold period of four months and one day from issuance.
FendX Technologies (CSE: FNDX) (OTCQB: FDXTF) has signed a non-binding LOI to acquire intellectual property including two patents related to BioFoam® technology and enter a supply agreement with US BioSolutions for eco-friendly sponge wipes. The transaction involves a US$75,000 cash payment and issuance of shares worth up to $200,000. The acquired technology offers washable, reusable sponge wipes that attract and trap pathogens when combined with cleaning agents. The deal is subject to conditions including due diligence, definitive agreements, regulatory approvals, and FendX completing a $1,000,000 financing.
FendX Technologies has been granted its fifth patent, specifically a US patent (No. 12,109,586) for its REPELWRAP™ film technology. The patent, titled 'Omniphobic Surfaces with Hierarchical Structures, and Methods of Making and Uses Thereof', was registered on October 8, 2024. Licensed exclusively from McMaster University, it protects the company's nanotechnology for creating repellent surfaces that have demonstrated reduced bacterial and viral contamination in laboratory testing. This development follows recent pilot manufacturing runs with Dunmore for REPELWRAP™ film as the company prepares for real-world beta testing.
FendX Technologies has signed a Letter of Intent (LOI) with Sinelabs to explore a non-exclusive distribution agreement for FendX's future surface protection products in the United States. Sinelabs, a South Carolina-based company specializing in water treatment solutions, has an established sales network in healthcare, hospitality, and senior living facilities - markets that align with FendX's target sectors. The agreement remains subject to negotiation and execution of definitive agreements, successful product development, and regulatory approvals. REPELWRAP™ film, FendX's lead product, is expected to enter real-world testing soon.
FendX Technologies announces the grant of its Japanese patent on October 10, 2024, marking its fourth patent for REPELWRAP™ film technology. The patent, numbered JP7570358, titled 'Omniphobic Surfaces with Hierarchical Structures, and Methods of Making and Uses Thereof,' is exclusively licensed from McMaster University. The technology involves a fluoropolymer-containing material designed to reduce surface contamination by minimizing bacteria and virus adhesion. The company recently completed pilot manufacturing runs with Dunmore and is preparing for real-world beta testing.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) has successfully completed its pilot manufacturing phase for REPELWRAP™ film in collaboration with Dunmore International Inc. The company is now advancing to real-world assessment of the film's repelling effectiveness at various test venues. This marks a important step towards finalizing the product for commercial production.
Dr. Carolyn Myers, CEO of FendX, expressed excitement about this milestone, emphasizing the importance of real-world testing in providing valuable insights into the film's performance. The company acknowledges the significant contributions of Dunmore International Corp. and McMaster University in reaching this stage of development.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) has announced the publication of research results demonstrating its AI-enhanced nanotechnology's ability to detect bacterial contamination on surfaces with 96.7% accuracy. The study, conducted at McMaster University, was peer-reviewed and published in 'Advanced Functional Materials' on July 30, 2024.
The technology, derived from FendX's licensed nanotechnology, incorporates a color-changing surface coating that transitions from blue to green-yellow to indicate bacterial biofilm formation. Using AI machine learning, it achieves 100% sensitivity and 95% accuracy in contamination detection.
Carolyn Myers, President and CEO of FendX, highlighted the potential of this technology for infection prevention and control in healthcare settings. The company also announced the resignation of Andrea Mulder as COO, effective August 30, 2024.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) has appointed Dr. Rohit Ramchandani as an advisor to leverage his extensive public health expertise in advancing innovative solutions for pathogen control and safety. Dr. Ramchandani, a global expert in public health and infectious disease control, brings nearly two decades of experience in designing, implementing, and scaling innovative approaches for disease control and health system strengthening.
His role at FendX will be to inform, advise, and support the company's mission to develop surface protection coatings that reduce pathogen spread. Dr. Ramchandani's expertise, particularly in pandemic response and antibiotic resistance, aligns with FendX's goal of addressing growing public health threats. His appointment is expected to contribute significantly to FendX's efforts in creating groundbreaking solutions for mitigating pathogen transmission and improving overall well-being.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) highlights a new CDC report showing a 20% increase in infections from six antibiotic-resistant bacteria ('superbugs') in 2021 and 2022 compared to 2019. The CDC attributes this rise partly to COVID-19's impact on healthcare systems, longer hospital stays, and antibiotic overuse.
The report emphasizes the need for more effective infection prevention and control strategies. FendX, a nanotechnology company developing surface protection coatings, aims to contribute to reducing superbug spread. Dr. Carolyn Myers, CEO of FendX, states that the company is dedicated to developing innovative high-touch surface protection solutions to combat superbug transmission and enhance safety.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) has successfully completed a pilot scale-up run of its REPELWRAP™ film with Dunmore International Corp. The company reports that the produced film met performance expectations using a streamlined manufacturing process. Dr. Carolyn Myers, CEO of FendX, expressed satisfaction with the progress and stated that this advancement brings them closer to real-world testing with various industry partners in long-term care, fitness, and entertainment sectors.
FendX plans to conduct another pilot manufacturing run with Dunmore in the coming weeks, which they believe will be the final run before advancing to real-world testing. The company acknowledges the valuable collaboration with Dunmore and McMaster University in reaching this stage. Additionally, FendX granted 55,000 restricted share units (RSUs) to a consultant, vesting in three equal installments over the next three months.
FAQ
What is the current stock price of FendX Technologies (FDXTF)?
What is the market cap of FendX Technologies (FDXTF)?
What does FendX Technologies Inc. specialize in?
What is REPELWRAP™ film?
Who are FendX's key collaborators?
What industries can benefit from FendX's products?
How does FendX protect its intellectual property?
What other products is FendX developing?
How does FendX ensure the effectiveness of its products?
What is FendX's approach to commercialization?
